No data available.
Please log in to see this content.
You have no subscription access to this content.
The full text of this article is not currently available.
Marked Improvements in HbA1c Levels by Alogliptin Monotherapy in a Cirrhotic Woman
Rent:
Rent this article for
JPY
Abstract
An 80‒year‒old woman with hepatitis C developed diabetes mellitus(DM)and initiated alogliptin monotherapy 25 mg/day. HbA1c improved from 10.2% to 9.5% by 4 weeks, 9.0% by 7 weeks, 8.5% by 11 weeks, 6.9% by 17 weeks, and 6.8% by 21 weeks. She however quitted alogliptin intake. As a result, the HbA1c levels gradually deteriorated from 6.8% to 7.9% by 6 weeks and to 9.4% by 10 weeks. Five months were required to reach stable status of DM control around HbA1c 6.5%(3.4% of improvements), and 10 weeks were required to worsen by 2.6%. The definite, gradual, and slow improvements in DM control as well as the gradual deterioration after quitting the monotherapy could be explained by recovered β cell proliferation in the Langerhans islet.
Full text loading...
/content/article/0289-8020/38060/649